in-PharmaTechnologist.com presents its latest round up of executive moves in the pharma sector, including appointments at Sanofi, GlaxoSmithKline, Croda and Provectus.
Former Henkel MD Jayant Singh has become GlaxoSmithKline Consumer Healthcare’s (GSKCH) new marketing director.
Singh returns to GSKCH after working in the Sri Lanka branch of the business. Before Henkel, he also worked for Gillette, Mars' European division as well as for Procter & Gamble.
He replaces former marketing director Shubhajit Sen, who will who will become vice-president of a new vertical-childhood growth and development.
Both appointments are part of GSKCH’s plans to focus its business into three verticals – childhood growth and development, specialist adult nutrition, and functional beverages.
David-Alexandre Gros is the new chief strategy officer at R&D specialists Sanofi.
Gros comes to Sanofi with experience as advisor to several pharmaceutical, biotechnology and diagnostic companies.
He is also a principal and founding member of the Healthcare Investment Banking division at Centerview Partners, in San Francisco
Sanofi’s chief executive Christopher Viehbacher said: “David-Alexandre brings a wealth of experience as a physician, strategic consultant and investment banker.
“He will be able to contribute significantly to the development and implementation of Sanofi’s strategy and transformation.”
Croda Europe president Steve Foots will take the helm as chief executive after the oleochemical manufacturer’s CE of 42-years, Mike Humphrey, stepped down.
Foots joined Croda as a graduate trainee in 1990 and was appointed Managing Director of Croda Europe Industrial Specialities in 2000, before joining Croda Europe Consumer Care in 2004.
He will take over the role in January, whilst Humphrey will remain as senior advisor.
Provectus Pharmaceuticals has drafted Alfred Smith into its Board of Directors.
Smith is currently a senior advisor the Marwood Group, Next Health, as well as K2 Global Consulting, and is a member of the Boards for the Tony Blair Faith Foundation and Mutual of America Capital Management Corporation.
Of his appointment to the development-stage oncology and dermatology company, he said: “As a new member of Provectus' Board of Directors, I am looking forward to focusing on bringing more visibility to the therapies it is developing to treat various forms of cancer.”
Sproxil have expanded its board of directors with three new additions; Gunther Faber, C. Hunter Boll and Nicholas Donofrio.
Faber – CEO of The HealthStore Foundation – is former Vice President at Sub-Saharan Africa for GlaxoSmithKline, and has more than 30 years of experience working within the pharmaceutical industry.
Donofrio is a senior fellow at the Ewing Marion Kauffman Foundation, and holds several other board positions.
Whilst Boll, a member of Acumen Fund’s Board of Directors, previously worked with the Boston Consulting Group and served as an assistant VP for the energy and mineral division of Chemical Bank.
A spokesperson for the U.S. based software company – who specialise in brand protection in emerging markets – said: “Each brings a background of extensive industry and consumer experiences that enrich the company’s mission and complement Sproxil’s efforts to provide a user-friendly solution that requires minimal education and training to use on the part of consumers.”